Education
About Us
Working with TipRanks
Follow Us
Anavex Life Sciences (AVXL)
NASDAQ:AVXL
Total Valuation
Anavex Life Sciences has a market cap or net worth of $753.67M. The enterprise value is $349.45M.
Market Cap$753.67M
Enterprise Value$349.45M
Share Statistics
Anavex Life Sciences has 85,064,200 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding85,064,200
Owned by Insiders3.30%
Owned by Institutions0.19%
Financial Efficiency
Anavex Life Sciences’s return on equity (ROE) is -0.36 and return on invested capital (ROIC) is 0.00%.
Return on Equity (ROE)-0.36
Return on Assets (ROA)-0.32
Return on Invested Capital (ROIC)0.00%
Return on Capital Employed (ROCE)0.00
Revenue Per Employee0.00
Profits Per Employee-1.02M
Employee Count42
Asset Turnover0.00
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of Anavex Life Sciences is -11.03. Anavex Life Sciences’s PEG ratio is 0.83.
PE Ratio-11.03
PS Ratio―
PB Ratio3.94
Price to Fair Value3.94
Price to FCF-15.39
Price to Operating Cash Flow-15.39
PEG Ratio0.83
Income Statement
In the last 12 months, Anavex Life Sciences had revenue of 0.00 and earned -43.00M in profits. Earnings per share was -0.52.
Revenue0.00
Gross Profit0.00
Operating Income0.00
Pretax Income-43.00M
Net Income-43.00M
EBITDA0.00
Earnings Per Share (EPS)-0.52
Cash Flow
In the last 12 months, operating cash flow was -35.61M and capital expenditures 0.00, giving a free cash flow of -35.61M billion.
Operating Cash Flow-35.61M
Free Cash Flow-35.61M
Free Cash Flow per Share-0.42
Dividends & Yields
Anavex Life Sciences pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta1.51
52-Week Price Change173.02%
50-Day Moving Average8.76
200-Day Moving Average7.75
Relative Strength Index (RSI)55.96
Average Volume (3m)1.21M
Important Dates
Anavex Life Sciences upcoming earnings date is May 8, 2025, TBA Not Confirmed.
Last Earnings DateFeb 12, 2025
Next Earnings DateMay 8, 2025
Ex-Dividend Date―
Financial Position
Anavex Life Sciences as a current ratio of 8.86, with Debt / Equity ratio of 0.00%
Current Ratio8.86
Quick Ratio8.86
Debt to Market Cap0.00
Net Debt to EBITDA0.00
Interest Coverage Ratio0.00
Taxes
In the past 12 months, Anavex Life Sciences has paid 0.00 in taxes.
Income Tax0.00
Effective Tax Rate0.00
Enterprise Valuation
Anavex Life Sciences EV to EBITDA ratio is 0.00, with an EV/FCF ratio of -11.10.
EV to Sales0.00
EV to EBITDA0.00
EV to Free Cash Flow-11.10
EV to Operating Cash Flow-11.10
Balance Sheet
Anavex Life Sciences has $120.78M in cash and marketable securities with $200.00K in debt, giving a net cash position of -$120.78M billion.
Cash & Marketable Securities$120.78M
Total Debt$200.00K
Net Cash-$120.78M
Net Cash Per Share-$1.42
Tangible Book Value Per Share$1.44
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
Gross Margin0.00%
Operating Margin0.00%
Pretax Margin0.00%
Net Profit Margin0.00%
EBITDA Margin0.00%
EBIT Margin0.00%
Analyst Forecast
The average price target for Anavex Life Sciences is $28.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$28.50
Price Target Upside206.12% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast―
EPS Growth Forecast-3.08%